“It is a major recognition for Iktos to be selected by Janssen as a partner for implementation and development of generative modelling technology for new drug design.” Janssen and Janssen have partnered to develop applications for small molecule drug discovery using Iktos' AI-based virtual design technology and Janssen 's expertise in AI-based prediction of small-molecule activities. Meanwhile, Iktos will release a beta version of its software as a service (SaaS) platform Iktos the middle of this year , while Janssen Pharmaceutica has developed AI-based methods that can replace human tasks, a move that will speed up drug discoveries.
Janssen and Janssen have partnered to develop applications for small molecule drug discovery using Iktos' AI-based virtual design technology and Janssen 's expertise in AI-based prediction of small-molecule activities. Meanwhile, Iktos will release a beta version of its software as a service (SaaS) platform Iktos the middle of this year , while Janssen Pharmaceutica has developed AI-based methods that can replace human tasks, a move that will speed up drug discoveries.